audeo: sketched potential for dilution, page-29

I have decided not to comment on these various question/inquiries, primarily because I want to use my Black Swan picture. If the display of my arrogant nature hasnt already peaked on this forum, its going to now when I say that I dont care about the science - the only thing I care about is making money. Its this reason alone that drives my investment decisions.

Now, due to this Chris, it is my belief that the CR is a certainty. I dont know what form it will take, it could be straight equity it could be hybrid/convertible debt. But its going to happen.

Alchemia does not have sufficent cash to fund its current clinical trials or preclinical studies to advance to commercial manufacture, whilst still operating as a stand alone business. Operating cash needs to be there to support Audeo.

Additionally there is significant uncertainty around how much Audeo can raise (due to market conditions) and how much it will raise (due to dilution). The interests of current Alchemia holders needs to be balanced against the need for Audeo capital.